Navigation Links
Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of the Total Pain Drug Market by 2023
Date:8/6/2008

Total Drug Market for Pain Will Reach More Than $47 Billion in 2023,

According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although strong opioids and non-steroidal anti-inflammatory drugs (NSAIDs) will continue to dominate the pain market over the next 15 years, novel drug classes will claim over one-fifth of total market share by 2023.

The new special Pharmacor report entitled Novel Approaches to Pain finds that the overall pain market will reach more than $47 billion in 2023 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. From 2008 to 2013, reformulations and emerging therapies in existing drug classes will be the primary drivers of market growth while from 2013 to 2023, growth will result predominantly from the launch of innovative agents representing entirely new drug classes. Therapies representing novel drug classes will expand the pain market by adding to the eight major analgesic drug classes, creating as many as 18 drug classes by 2023, according to the report.

The most successful reformulations and emerging therapies in existing drug classes will be abuse- and dependence-resistant strong opioid formulations, including King Pharmaceuticals/Pain Therapeutics' Remoxy; as well as safer and more tolerable NSAID formulations such as NicOx's naproxcinod and AstraZeneca/POZEN's naproxen/esomeprazole combination; Johnson & Johnson's new dual-acting opioid tapentadol; and longer lasting antimigraine formulations such as GlaxoSmithKline's Treximet.

Of the novel drug classes expected to launch for pain through 2023, the calcitonin gene-related peptide receptor antagonists, growth factor modulators, and subtype-selective ion channel modulators will have the most growth impact owing to their potential efficacy advantages over existing drug classes. All three of these novel drug classes are forecast to attain blockbuster peak-year sales.

"The most commercially promising drugs with novel mechanisms of action are being developed for the treatment of chronic pain that is either inflammatory or neuropathic in origin," said Natalie Taylor, Ph.D., analyst at Decision Resources. "Current therapies for inflammatory pain, such as the NSAID drug class, are plagued by safety concerns when administered over the long-term, while current therapies for neuropathic pain, such as antidepressants and anti-epileptics, are associated with inconsistent efficacy."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Despite Bad Economy Botox Sales Are Booming
2. Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008
3. P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth
4. FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008
5. Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income
6. VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales
7. Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively
8. Milestone Scientific Expands Domestic Sales Network With Addition of Three New Dental Distributors
9. Procter & Gamble Confirms Prior Sales and Earnings Guidance for Fourth Quarter 2007/08
10. Longs Reports Preliminary June Retail Drug Store Sales
11. New Research Covers Current Trends and Future Directions of the High Performing Pharmaceutical District Sales Managers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... College District , the only authorized OSHA Training Institute Education Center headquartered in ... by protecting their workers from extreme heat at their worksites. Employers with ...
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... professionals, announced today its affiliation with Tennessee Counseling Association. This new ... network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology: